

CURRICULUM VITAE

Jess Thomas Whitson, M.D., F.A.C.S.

Present Position: Professor of Ophthalmology
UT Southwestern Medical Center at Dallas

Address: Department of Ophthalmology
5323 Harry Hines Boulevard
Dallas, Texas 75390

Telephone: (214) 648-4733
Facsimile: (214) 648-2469

Medical Licensure: Texas H2900, 1987

Board Certification: American Board of Ophthalmology, 1992
Certificate renewal, 2002, 2012

Employment

1992-1993 Department of Surgery, Southern Illinois
University School of Medicine
Assistant Professor

1993- Department of Ophthalmology
UT Southwestern Medical Center at Dallas

1993-2000 Assistant Professor

2000-2008 Associate Professor

2008- Professor

Education

Undergraduate: Bachelor of Arts
Johns Hopkins University
September 1981 to May 1983

Medical School: Doctor of Medicine
Johns Hopkins University
September 1983 to September 1986

Postgraduate Training

Internship:	Department of Medicine UT Southwestern Medical Center at Dallas July 1986 to June 1987
Pre-residency/ Research Fellowship:	Department of Ophthalmology UT Southwestern Medical Center at Dallas July 1987 to June 1988
Residency:	Department of Ophthalmology UT Southwestern Medical Center at Dallas July 1988 to June 1991
Fellowship:	Glaucoma Department of Ophthalmology Emory University July 1991 to June 1992
Other Studies:	Training Certificate in Public Health Practice Bloomberg School of Public Health Johns Hopkins University January 2005 to December 2006 Graduate Certificate in Finance Edwin L. Cox School of Business Southern Methodist University September 2006 to March 2007 Life Sciences Entrepreneurial Management Certificate Jesse H. Jones Graduate School of Management Rice University April 2008 to May 2008

Honors and Awards

Listed, Texas Super Doctors 2010-11
Listed, *Guide to America's Top Ophthalmologists* 2007-11,
Consumers' Research Council of America
Listed, *Best Doctors in America*, 2003-12, Woodward-White, Inc.
Listed, *Who's Who Among Executives and Professionals*, 2011
Achievement Award, American Academy of Ophthalmology
Alpha Omega Alpha Medical Honor Society
Phi Eta Sigma National Honor Society (Chapter President)
Sophomore Scholarship Award, University of Arizona
Dean's List, University of Arizona
Fraternal Order of Eagles Scholarship
Salutatorian Award, Sunnyslope High School, Phoenix, Arizona

Professional Societies

American Academy of Ophthalmology
Annual Meeting Program Committee, 2007-11
American Eye Study Club
American Glaucoma Society
Association of University Professors of Ophthalmology
BioDFW
Dallas County Medical Society
Dallas Academy of Ophthalmology
Program Chairman, 2006-07
Secretary/Treasurer, 2007-08
Vice President, 2008-09
President, 2009-10
Past President, 2010-11
Board of Directors, 2011-14
Diplomate, American Board of Ophthalmology
European Glaucoma Society
Fellow, American College of Surgeons
Johns Hopkins Medical and Surgical Society
North Texas Eye Research Institute

Peer Review Activities

Archives of Ophthalmology
American Journal of Ophthalmology
British Journal of Ophthalmology
Clinical Ophthalmology
Eye and Contact Lens
Journal of Glaucoma
Ophthalmology
Survey of Ophthalmology

Institutional Service

UT Southwestern Medical Center and Department of
Ophthalmology Committees
Resident Selection Committee, 1993-2006, 2008
Surgical Peer Review Committee, 1993-2006
Medical School Curriculum Committee, 1993-94
Surgical Services Performance Improvement Committee,
1993-94
Clinical Quality Improvement Committee, 1994-2005
Systems and Service Quality Improvement Committee, 2000
Medical Directors Clinical Operations Committee, 2003-
Ambulatory Performance Improvement Committee, 2009-11
Director, Glaucoma Fellowship Program, 1993-
Director/Coordinator, Medical Student Education in
Ophthalmology, 1994-
Alternate Representative, Faculty Senate, 2000-03
Representative, Faculty Senate, 2003-06
UT Southwestern Hospitals Surgery Best Practice/Peer Review
Committee, 2006-
Surgical Peer Review Committee, Children's Medical Center Dallas,
2008-10

U.S. Medical Board Examiner

Associate Examiner, American Board of Ophthalmology, 2005-

Speakers Bureau

Alcon Laboratories
Allergan
Bausch and Lomb Pharmaceuticals
Lumenis
Merck and Co.
Novartis Pharmaceuticals
Pfizer

Hospital Appointments

Children's Medical Center
John Peter Smith Hospital
Parkland Memorial Hospital
St. Paul University Hospital
Veteran's Affairs Hospital

Peer-Reviewed Research Papers (Pubmed Citations)

1. Whitson JT, Welch RB, Green WR. Von Hippel-Lindau disease: case report of a patient with spontaneous regression of a retinal angioma. *Retina* 1986; 6:253-259.
2. Lynch MG, Whitson JT, Brown RH, Nguyen HL, Drake MM. Topical beta-blocker therapy and CNS side effects. *Arch Ophthalmol* 1988; 106:908-911.
3. Whitson JT, Love R, Brown RH, Lynch MG, Schoenwald RD. The effect of reduced eye drop size and eyelid closure on the therapeutic index of phenylephrine. *Am J Ophthalmol* 1993; 115:357-359.
4. Hoehner PJ, Whitson JT, Kirsch JR, Traystman RJ. Effect of intracarotid and intraventricular morphine on regional cerebral blood flow and metabolism in pentobarbital-anesthetized dogs. *Anesth Analg* 1993; 76:266-273.
5. Whitson JT. Recent developments in glaucoma drainage implant surgery. *Int Ophthalmology Clinics* 1999; 39:43-55.

6. Fellman RL, Sullivan EK, Ratliff M, Lewis HS, Whitson JT, Turner FD, Weiner AL, Davis AA, and the Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated IOP: a six-month, masked, multicenter trial. *Ophthalmology* 2002;109(5):998-1008.
7. Whitson JT. Travoprost - a new prostaglandin analogue for the treatment of glaucoma. *Expert Opin Pharmacother* (England) 2002;3(7):965-977.
8. Song J, Stinnett SS, Whitson JT, Kooner KS. Ten-year surgical experience in childhood glaucoma. *J Ped Ophthalmol Strabismus* 2003;40:11-18.
9. Whitson JT, McCulley JP, Cavanagh HD, Song J, Bowman RW, Hertzog L. Effect of laser in situ keratomileusis on optic nerve head topography and retinal nerve fiber layer thickness. *J Cat Refr Surg* 2003;29:2302-2305.
10. Whitson JT, Henry C, Hughes B, Lee DA, Terry S, Fechtner RD. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. *J Glaucoma* 2004;13:168-173.
11. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. *Drugs Aging* 2005;22:1-21.
12. Whitson JT, Liang C, Godfrey DG, Petroll WM, Cavanagh HD, Patel D, Fellman RL, Starita RJ. Central corneal thickness in patients with congenital aniridia. *Eye Contact Lens* 2005;31:221-224.
13. Hollo G, Whitson JT, Faulkner R, McCue B, Curtis M, Weiland H, Chastain J, Sanders M, DeSantis L, Przydryga J, Dahlin DC. Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. *Invest Ophthalmol Vis Sci* 2006;47:235-40.
14. Kelley PS, Dossey AP, Patel D, Whitson JT, Hogan RN, Cavanagh HD. Secondary glaucoma associated with advanced acanthamoeba keratitis. *Eye Contact Lens* 2006;32:178-82.

15. Whitson JT, James J, Andrew R, Wells D, Dickerson J, Landry T, Bergamini M. A comparison of brimonidine tartrate ophthalmic solution 0.15% to ALPHAGAN® P in patients with open-angle glaucoma or ocular hypertension. *Ophthalmology* 2006;113:1333-9.
16. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. *Adv Ther* 2006;23:663-71.
17. Gallardo MJ, Aggarwal NK, Whitson JT. Progression of glaucoma associated with the Sirsasana (headstand posture) yoga position. *Adv Ther* 2006;23:921-25.
18. Kramar M, Vu L, Whitson JT, He Y-G. The effect of intravitreal triamcinolone on intraocular pressure. *Curr Med Res Opin* 2007;23:1253-1258.
19. Whitson JT. Glaucoma: A review of adjunctive therapy and new management strategies. *Expert Opin Pharmacother* (England) 2007;8(18):3237-49.
20. Whitson JT, Roarty JD, Vijaya L, Robin AL, Gross RD, Landry TA, Dickerson JE, Scheib SA, Scott H, Hua SY, Woodside A, Bergamini MVW for the Brinzolamide Pediatric Study Group. Efficacy of brinzolamide in pediatric glaucomas: a randomized clinical trial. *J AAPOS* 2008 Jun;12(3):239-246.
21. Di Pascuale MA, Whitson JT, Mootha V. Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. *Eye Contact Lens* 2008;34(2):129-30.
22. Rhodes KM, Weinstein R, Saltzmann RM, Aggarwal N, Kooner KS, Petroll WM, Whitson JT. Intraocular pressure reduction in the untreated fellow eye after selective laser trabeculoplasty. *Curr Med Res Opin* 2009;25(3):787-796.
23. Plager DA, Whitson JT, Netland PA, Vijaya L, Sathyan P, Sood P, Krishnadas SR, Robin AL, Gross RD, Scheib SA, Scott H, Dickerson JE and the BETOPTIC-S Pediatric Study Group. Efficacy of betaxolol 0.25% ophthalmic suspension and timolol gel forming solution 0.25% and 0.5% in pediatric glaucoma: a randomized clinical trial. *J AAPOS* 2009 Aug;13(4):384-90.

24. Faulkner R, Sharif NA, Orr S, Sall K, Dubiner H, Whitson JT, Moster M, Craven ER, Curtis M, Pailliotet C, Martens K, Dahlin D. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN® or TRAVATAN®. *J Ocul Pharm Ther* 2010 Apr;26(2):147-56.
25. Whitson JT, et al. Ocular Surface Tolerability of Prostaglandin Analogs in Patients with Glaucoma or Ocular Hypertension. *J Ocul Pharm Ther* 2010 Jun;26(3):287-92.
26. Allen MB, Lieu P, Muftuoglu O, Mootha VV, Bowman RW, Petroll WM, Cavanagh HD, Whitson JT, Aggarwal NK. Risk factors for intraocular pressure elevation following Descemet stripping endothelial keratoplasty. *Eye Contact Lens*. 2010 Jul;36(4):223-7.
27. Saltzmann R, Weakley DR, Whitson JT. Incidence, risk factors, and outcomes of glaucoma following congenital cataract surgery. *J Pediatr Ophthalmol Strabismus* 2011;48:142-49.
28. Ali Z, Whitson JT, Mootha VV, Witherspoon SR, Joseph JA, Joseph AM, Hynan L, Cavanagh HD. The prevalence of primary open-angle glaucoma in patients with corneal endothelial dystrophy. In press, *Eye Contact Lens*.
29. Saltzmann R, Whitson JT. Long-term outcomes of trabeculotomy ab externo for congenital glaucoma. Manuscript in preparation.

Scientific Presentations

1. Whitson JT, Love R, Brown RH, Lynch MG, Schoenwald RD. The effect of eye drop size and eyelid closure on pupillary dilation and systemic absorption of topical phenylephrine (poster). Association for Research in Vision and Ophthalmology, Sarasota, FL, 1988.
2. Lynch MG, Whitson JT, Brown RH, Nguyen HL, Drake MM. Topical beta-blocker therapy and CNS side effects (poster). Third Congress of the European Glaucoma Society, Estoril, Portugal, 1988.

3. Whitson JT, Lynch MG, Brown RH, Nguyen HL. The effect of coffee on intraocular pressure (poster). American Academy of Ophthalmology annual meeting, Las Vegas, NV, 1988.
4. Whitson JT, Kennedy RH, Kooner KS, McCulley JP. Phacoemulsification by residents in ophthalmology (paper). Association for Research in Vision and Ophthalmology, Sarasota, FL, 1990.
5. Whitson JT, Anand R, McCulley JP. Penetrating ocular trauma at Parkland Memorial Hospital: a retrospective analysis (poster). Association for Research in Vision and Ophthalmology, Sarasota, FL, 1991.
6. Whitson JT. The use of mitomycin-c in glaucoma filtration surgery (paper) Texas Medical Association annual meeting, Austin, TX, 1994.
7. Whitson JT, Moninger GA. A six-year review of penetrating ocular trauma (poster) Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 1995.
8. Pham JT, Whitson JT, Kooner KS, Blumenfeld DG. The efficacy of laser peripheral iridectomy in pigmentary glaucoma (poster) Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 1996.
9. Wang D, Whitson JT, Allingham RR. Family history of glaucoma as a prognostic factor in open angle glaucoma patients (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 1996.
10. Whitson JT, Li L, Park SS. Elevated TGF-beta levels in aqueous humor of human eyes with failed filtration bleb (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 1996.
11. Neely DE, Abbasoglu O, Barke RM, Whitson JT. Vitreous loss by resident surgeons during cataract surgery (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 1996.
12. Wang D, Whitson JT, Allingham RR, McIntire D. Family history of glaucoma as a prognostic factor in primary open angle glaucoma. American Academy of Ophthalmology annual meeting, Chicago, IL 1996.

13. Wang D, Whitson JT, Allingham RR. The incidence of glaucoma among patients with increased cup to disc ratio on initial presentation (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 1997.
14. Whitson JT. The role of peripheral iridectomy in the treatment of pigmentary glaucoma (paper). Texas Medical Association annual meeting, Houston, TX, 1997.
15. Whitson JT, Ford DT. Intraocular pressure following cataract surgery: a retrospective review (paper). American Academy of Ophthalmology annual meeting, Orlando, FL, 1999.
16. Chundru RK, Agarwal R, Wordinger RJ, Whitson JT. Detection of neurotrophins in human aqueous humor (paper). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2000.
17. Whitson JT, Stokes JP. A retrospective comparison of Cosopt to concomitant usage of a non-selective topical beta-blocker and dorzolamide in a diverse glaucoma patient population (poster). Sixth Congress of the European Glaucoma Society, London, England, 2000.
18. Song J, Whitson JT, Kooner KS. Surgical results in childhood glaucoma (paper). American Society of Cataract and Refractive Surgery annual meeting, San Diego, CA, 2001.
19. Shen JF, Whitson JT, El Agha MS, Kooner KS, Hargrave SL, Bowman RW, Cavanagh HD, McCulley JP. Glaucoma tube shunt placement In the setting of penetrating keratoplasty: a retrospective review (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2001.
20. Whitson JT, Ratliff M, Fellman RL, Sullivan EK, Turner FD, Silver LH, Weiner AL, and the Travoprost Study Group. Travoprost, a new prostaglandin analog is superior to timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2001.

21. Hazelton JR, Ritter R, Whitson JT, Ogawa GSH, Donoso LA, Edwards AO. Axenfeld-Rieger syndrome in a family caused by Haploinsufficiency (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2001.
22. Hollo G, Whitson J, Faulkner R, Wieland H, McCarty G, DeSantis L, Przydryga J, Dahlin D. Betaxolol distributes to the retina, optic nerve head, and choroid of the human eye following chronic topical administration of Betoptic-S (poster). European Association for Ophthalmology and Eye Research, Alicante, Spain, 2001.
23. Whitson JT, McCulley JP, Cavanagh HD, Song J, Bowman RW, Hertzog L. Effect of betaxolol on optic nerve head topography and retinal nerve fiber layer thickness during LASIK (paper). Texas Medical Association annual meeting, Dallas, TX, 2002.
24. Whitson JT, Hollo G, Faulkner R, Curtis M, McCue B, Wieland H, DeSantis L, Przydryga J, Dahlin DC. Distribution of betaxolol to the human retina, optic nerve head and choroid following multiple topical ocular administration of Betoptic-S (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2002.
25. Hazelton JT, Whitson JT, Henry C, Terry S, Hughes B, Lee DA. Comparison of the intraocular pressure effect and safety of dorzolamide 2% versus brimonidine 0.2% each given three times daily for six weeks in patients with primary open-angle glaucoma or ocular hypertension (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2002
26. Awan MH, Whitson JT, McCulley JP, Bowman RW, Cavanagh HD, Song J, Hertzog L. Effect of betaxolol on optic nerve head topography and retinal nerve fiber layer thickness during LASIK (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2002.
27. Whitson JT, Henry C, Hughes B, Lee DA, Terry S. Comparison of the intraocular pressure (IOP) effect and safety of dorzolamide 2% versus brimonidine 0.2% each given three times daily for six weeks in patients with primary open-angle glaucoma or ocular hypertension (poster). American Academy of Ophthalmology annual meeting, Orlando, FL, October 20-23, 2002

28. Hollo G, Whitson JT, Faulkner R, Curtis M, Wieland H, DeSantis L, McCue B, Przydryga JT, Dahlin DC. Betaxolol distributes to the human retina and optic nerve head at pharmacologically active levels after chronic topical ocular administration of Betoptic-S (poster). 4th International Glaucoma Symposium, Barcelona, Spain, March 19-22, 2003.
29. Patel D, Whitson JT. Treatment of reverse pupillary-block glaucoma caused by anteriorly dislocated crystalline lens (poster). American Society of Cataract and Refractive Surgery annual meeting, San Francisco, CA April 12-16, 2003.
30. Whitson JT, Godfrey DG, Patel P, Fellman RL, Starita RJ. Central corneal thickness in patients with congenital aniridia (poster). American Academy of Ophthalmology annual meeting, Anaheim, CA, November 14-18, 2003.
31. Patel D, Whitson JT, Dossey AP, Cavanagh HD. Management of secondary glaucoma in patients with acanthamoeba keratitis (poster). American Academy of Ophthalmology annual meeting, Anaheim, CA, November 14-18, 2003.
32. Whitson JT, Godfrey DG, Patel D, Fellman RL, Starita RJ. Central corneal thickness in patients with congenital aniridia (poster). American Glaucoma Society annual meeting, Sarasota, FL, March 4-7, 2004.
33. Parmar D, Awwad ST, Heilman M, Whitson JT, Cavanagh HD. Blindness from acanthamoeba (poster). American Society of Cataract and Refractive Surgery annual meeting, San Diego, CA, May 1 – 5, 2004.
34. Dahlin DC, Craven ER, Moster M, Sall K, Whitson JT, Betham R, Curtis M, Faulkner R, Orr S. Human aqueous humor concentrations of bimatoprost and bimatoprost free acid following topical ocular dosing of Lumigan (17-phenyl-trinor-PGF_{2α}) 0.03% ophthalmic solution (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2004.
35. Dossey AP, Patel D, Whitson JT, Cavanagh HD. Secondary glaucoma associated with acanthamoeba keratitis (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, 2004.

36. Whitson JT, Ochsner KI, Sullivan EK, Andrew R, Silver LH, Wells D, James JE, Bosworth C, Dickerson JE, Landry TA, Bergamini MVW. The safety and IOP lowering efficacy of brimonidine tartrate 0.15% preserved with polyquarternium-1 compared to Alphagan® P in patients with OAG or OHT (poster). American Academy of Ophthalmology annual meeting, New Orleans, LA, Oct 22-25, 2004.
37. Kramar M, He Y, Whitson JT. The effect of intravitreal triamcinolone acetonide on intraocular pressure (paper). American Glaucoma Society annual meeting, Snowbird, UT, March 3 – 6, 2005.
38. Whitson JT, Ochsner KI, Moster MR, James JE, Andrew RM, Wells D, Dickerson JE, Landry TA, Bergamini MVW. Brimonidine tartrate ophthalmic solution 0.15% preserved with polyquaternium-1 compared to Alphagan® P in patients with OAG or OHT: six month safety and efficacy results (poster). American Glaucoma Society annual meeting, Snowbird, UT, March 3 – 6, 2005.
39. Younger JR, Whitson JT. Retinal nerve fiber layer thickness in Hispanic glaucoma suspects (poster). American Glaucoma Society annual meeting, Charleston, SC, March 2 – 5, 2006.
40. Whitson JT, Cavanagh HD, Petroll WM. Assessment of corneal epithelial integrity following acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride (poster). International Congress on Glaucoma Surgery, Toronto, Canada, May 25 – 28, 2006.
41. Whitson JT, Roarty JD, Vijaya L, Gross RD, Scott H, Scheib SA, Dickerson JE, Landry TA, Bergamini MVW. The efficacy of brinzolamide in the treatment of pediatric glaucoma (poster). American Academy of Ophthalmology annual meeting, Las Vegas, NV, November 11 – 14, 2006.
42. Weinstein RJ, Whitson JT, Aggarwal N, Petroll M. Effect of selective laser trabeculoplasty on the intraocular pressure in the untreated fellow eye (poster). American Glaucoma Society annual meeting, San Francisco, CA, March 1 – 4, 2007.
43. Lee OA, Whitson JT. Clinical outcomes of Ahmed glaucoma implant in refractory pediatric glaucoma (poster). American Glaucoma Society annual meeting, San Francisco, CA, March 1 – 4, 2007.

44. Di Pascuale MA, Whitson JT, Mootha V. Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery (poster). American Society of Cataract and Refractive Surgery annual meeting, San Diego, CA, April 27 – May 2, 2007.
45. Weinstein RJ, Whitson JT, Aggarwal N, Petroll M. Effect of selective laser trabeculoplasty on the intraocular pressure in the untreated fellow eye (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, May 6 – 9, 2007.
46. Saltzmann RM, Whitson JT. Incidence, risk factors, and outcomes of glaucoma following congenital cataract surgery (poster). American Glaucoma Society annual meeting, Washington DC, March 6 – 9, 2008.
47. Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA. Ocular surface tolerability of prostaglandin analogues (PGAs) in patients with glaucoma or ocular hypertension (poster). American Glaucoma Society annual meeting, San Diego, CA, March 5 – 8, 2009.
48. Saltzmann RM, Whitson JT, Wax MB. Pneumatography in normal pressure glaucoma (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, May 3 – 7, 2009.
49. Dao LM, Sullivan B, Whitson JT. Legal blindness among Vietnam, Gulf (Desert Storm), Afghanistan, and Iraq war veterans. Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, May 3 – 7, 2009.
50. Saltzmann RM, Reinecke SR, Whitson JT. Long-term outcomes of primary trabeculotomy for congenital glaucoma at Children's Medical Center (poster). American Glaucoma Society annual meeting, Naples, FL, March 4 – 7, 2010.
51. Saltzmann RM, Reinecke SR, Whitson JT. Long-term outcomes of primary trabeculotomy for congenital glaucoma at Children's Medical Center (poster). Association for Research in Vision and Ophthalmology, Ft Lauderdale, FL, May 2 – 6, 2010.

52. Ali Z, Whitson JT, Mootha VV, Witherspoon SR, Joseph JA, Joseph AM, Hynan L, Cavanagh HD. The prevalence of primary open-angle glaucoma in patients with corneal endothelial dystrophy (paper). Cornea Society/EBAA Fall Educational Symposium, Chicago, IL, October 15, 2010.
53. Roensch MA, Kooner KS, Prasla Z, Harrison M, Whitson JT. Characteristics of childhood glaucoma (poster). American Academy of Ophthalmology annual meeting, Chicago, IL, October 16 – 19, 2010.

ARVO Abstracts

1. Whitson JT, Love R, Brown RH, Lynch MG, Schoenwald RD. The effect of eyedrop size and eyelid closure on pupillary dilatation and systemic absorption of topical phenylephrine. *Invest Ophthalmol Vis Sci* 1988; 29(suppl):106.
2. Whitson JT, Kennedy RH, Kooner KS, McCulley JP. Phacoemulsification by residents in ophthalmology. *Invest Ophthalmol Vis Sci* 1990; 31(suppl):1167.
3. Whitson JT, Anand R, Kennedy RH, McCulley JP. Visual outcome and incidence of enucleation following penetrating ocular trauma. *Invest Ophthalmol Vis Sci* 1991; 32(suppl):1066.
4. Whitson JT, Moninger GA. A six-year review of penetrating ocular trauma. *Invest Ophthalmol Vis Sci* 1995; 36(suppl):2358.
5. Whitson JT, Li L, Park SS. Elevated TGF-beta levels in aqueous humor of human eyes with failed filtration bleb. *Invest Ophthalmol Vis Sci* 1996; 37(suppl):120.
6. Pham JT, Whitson JT, Kooner KS, Blumenfeld DG. The efficacy of laser peripheral iridotomy in pigmentary glaucoma. *Invest Ophthalmol Vis Sci* 1996; 37(suppl):1198.
7. Wang D, Whitson JT, Allingham RR, McIntire DD. Family history of glaucoma as a prognostic factor in primary open angle glaucoma. *Invest Ophthalmol Vis Sci* 1996; 37(suppl):1908.

8. Neely DE, Abbasoglu O, Barke RM, Whitson JT. Vitreous loss by resident surgeons during cataract surgery. *Invest Ophthalmol Vis Sci* 1996; 37(suppl):2701.
9. Wang D, Whitson JT, Allingham RR. The incidence of glaucoma among patients with increased cup to disc ratio on initial presentation. *Invest Ophthalmol Vis Sci* 1997; 38(suppl):4918.
10. Chundru RK, Agarwal R, Wordinger RJ, Whitson JT. Detection of neurotrophins in human aqueous humor. *Invest Ophthalmol Vis Sci* 2000; 41(suppl):1719.
11. Shen JF, Whitson JT, El Agha MS, Kooner KS, Hargrave SL, Bowman RW, Cavanagh HD, McCulley JP. Glaucoma tube shunt placement in the setting of penetrating keratoplasty: a retrospective review. *Invest Ophthalmol Vis Sci* 2001; 42(suppl):2260.
12. Whitson JT, Ratliff M, Fellman RL, Sullivan EK, Turner FD, Silver LH, Weiner AL. Travoprost, a new prostaglandin analogue, is superior to timolol in lowering IOP in patients with open-angle glaucoma or ocular hypertension. *Invest Ophthalmol Vis Sci* 2001; 42(suppl):2989.
13. Hazelton JR, Ritter R, Whitson JT, Ogawa GSH, Donoso LA, Edwards AO. Axenfeld-Rieger syndrome in a family caused by haploinsufficiency. *Invest Ophthalmol Vis Sci* 2001; 42:3021.
14. Awan MH, Whitson JP, McCulley JP, Bowman RW, Cavanagh HD, Song J, Hertzog L. Effect of betaxolol on optic nerve head topography and retinal nerve fiber layer thickness during LASIK. ARVO 2002, abstract 2100.
15. Whitson JT, Hollo G, Faulkner R, Curtin M, McCue B, Wieland H, DeSantis L, Przydryga L, Dahlin DC. Distribution of betaxolol to the human retina, optic nerve head and choroid following multiple topical ocular administration of Betoptic S. ARVO 2002, abstract 4094.
16. Hazelton JR, Whitson JT, Henry C, Terry S, Hughes B, Lee DA. Comparison of the intraocular pressure effect and safety of dorzolamide 2% versus brimonidine 0.2% each given three times daily for six weeks in patients with primary open-angle glaucoma or ocular hypertension. ARVO 2002, abstract 4098.

17. Dahlin DC, Craven ER, Moster M, Sall K, Whitson JT, Betham R, Curtis M, Faulkner R, Orr S. Human aqueous humor concentrations of bimatoprost and bimatoprost free acid following topical ocular dosing of Lumigan (17-phenyl-trinor-PGF_{2α}) 0.03% ophthalmic solution. ARVO 2004, abstract 2096, poster #B907.
18. Dossey AP, Patel D, Whitson JT, Cavanagh HD. Secondary glaucoma associated with acanthamoeba keratitis. ARVO 2004, abstract 5533, poster #B857.
19. Weinstein RJ, Whitson JT, Aggarwal N, Petroll M. Effect of selective laser trabeculoplasty on the intraocular pressure in the untreated fellow eye. ARVO 2007, abstract 3977, poster #B957.
20. Saltzmann RM, Whitson JT, Wax MB. Pneumatography in normal pressure glaucoma. ARVO 2009, abstract 2850, poster #A184.
21. Dao LM, Sullivan B, Whitson JT. Legal blindness among Vietnam, Gulf (Desert Storm), Afghanistan, and Iraq war veterans. ARVO 2009, abstract 3201, poster #A392.
22. Saltzmann RM, Reinecke SR, Whitson JT. Long-term outcomes of primary trabeculotomy for congenital glaucoma at Children's Medical Center. ARVO 2010, abstract 605/449, poster #124.

Book chapters

1. Whitson JT. Pigmentary glaucoma. In: Zimmerman TJ, Kooner KS, eds. *Clinical Pathways in Glaucoma*. New York-Stuttgart: Thieme Publishing Co., 2000, pp. 175 – 183.
2. Whitson JT, Aggarwal NK. Pharmacological therapies for managing glaucoma. In: *Mechanisms of the Glaucomas*, Tombran-Tink, Joyce; Barnstable, Colin J.; Shields, M. Bruce (eds.), Humana Press, 2008, pp. 611 – 644.
3. Whitson JT. How should I treat the glaucoma patient with topical drug allergies? In: *Curbside Consults in Glaucoma*, Heuer, D.K.; Gedde, S.J.; Lewis, R.A. (eds.), Slack Inc., 2008, pp. 151 – 154.

4. Whitson JT. Choosing adjunctive glaucoma therapy. In: *The Glaucoma Book*, Schacknow P.; Samples J. (eds.), Springer, 2010, pp. 629 – 641.
5. Whitson JT. Visual loss following glaucoma drainage implant surgery. In: *Operative Complications in Glaucoma, Vol 1: Complications of Glaucoma Surgery*, Oxford University Press, Spring, 2011.

Monographs, Supplements and Non Peer-Reviewed Articles

1. Whitson JT. Glaucoma drainage implant surgery: perspectives for the new millennium. *Search on Glaucoma (Germany)* 2000;8:31-37.
2. Therapeutic Considerations in Glaucoma Management: Focus on Neuroprotection. Roundtable discussion and supplement to *Ocular Surgery News*, November 1, 2001.
3. Realini T, Whitson JT. Ocular blood flow in glaucoma and macular degeneration: evidence-based clinical applications. Supplement to *Ophthalmology Times*, Volume 28, Suppl. 4, June 15, 2003.
4. Whitson JT. Current trends in glaucoma management. Supplement to *Eyeworld*, Volume 8, No. 8, August 2003.
5. Whitson JT. Travoprost - a new prostaglandin analogue for the treatment of glaucoma. *Search on Glaucoma (Germany)* 2003;11:4-15.
6. Whitson JT. Carbonic anhydrase inhibitors as adjunctive therapy for glaucoma. *Glaucoma Management News*, Volume 1, No. 4, September 2003.
7. Whitson JT. Glaucoma: new directions in medical and surgical treatment. *Clinical Perspectives*, Volume XII, No. 1, Spring/Summer 2004, UT Southwestern Medical Center at Dallas.
8. Whitson JT, Netland PA, Hermes DeSantis ER. When and what to add to prostaglandin therapy. *Review of Ophthalmology*, Volume 12, No. 8, pp. 62 – 69, August 2005.

9. Gallardo MJ, Fiscella RG, Whitson JT. Generic glaucoma medications: is it safe to switch? *Glaucoma Today*, Volume 4, No. 1, pp. 32 – 35, January/February 2006.
10. Aggarwal NK, Whitson JT. Secondary glaucoma in a child with microcornea and aphakia. *Glaucoma Today*, Volume 4, No. 2, pp. 26 – 28, March/April 2006.
11. Whitson JT. Travatan Z solution proven less toxic to the ocular surface. In Trends in Glaucoma Treatment, Supplement to *EyeWorld*, Volume 11, No. 10, October 2006.
12. Whitson JT, Varner DW, Netland, PA. Glaucoma drugs and the ocular surface. *Review of Ophthalmology*, Volume 13, No. 11, pp. 69 – 77, November 2006.
13. Fantes FE, Lewis RA, Whitson JT. Improving ocular surface health in glaucoma patients. *Ophthalmology Management*, Volume 11, No. 2, pp. 77 – 78, February 2007.
14. Ford DT, Whitson JT. The effect of uncomplicated cataract surgery on intraocular pressure: a retrospective review. *Clinical and Surgical Ophthalmology*, Volume 25, No. 4, pp.130 – 134, April 2007.
15. Whitson JT. Adjuncts to prostaglandins offer expanded glaucoma treatment options. *Ocular Surgery News*, Volume 26, No. 2, pp. 31 – 36, January 25, 2008.
16. Whitson JT. Evolving clinical experience with BAK-free IOP-lowering glaucoma medications. *Ocular Surgery News*, Volume 27, No. 3, pg. 20, February 10, 2009.
17. Whitson JT. Investigating neuroprotective treatments for glaucoma. *Refractive Eyecare*, Volume 13, No. 9, pp. 29 – 30, September 2009.
18. Budenz DL, Whitson JT. Expert perspectives: focus on adjunctive therapy in glaucoma. Akita Biomedical Consulting, pp. 1 – 22, 2010.
19. Springs CL, Whitson JT. Glaucoma case reviews: identification and management of ocular surface disease in the glaucoma patient. Akita Biomedical Consulting, pp. 1 – 22, 2010.

20. Reiss GR, Sit AJ, Whitson JT. The strengths and challenges of glaucoma care today. *Glaucoma Today*, Vol. 9, No. 2 , pp., February 2011.
21. Kooner KS, Joseph A, Shar A, Marquardt FA, AlBdoor M, Cho BJ, Whitson JT, Aggarwal N, Adams-Huet B. (2011) Dallas Glaucoma Registry: Preliminary Results. *J Clinic Experiment Ophthalmol* 2:164. doi:10.4172/2155-9570.1000164
22. Sloan CF, Patel SS, Whitson JT. Recent advances in the treatment of pediatric glaucoma. American Academy of Ophthalmology, ONE Network, Current Insight, Summer 2011. <http://one.aaopt.org/CE/News/CurrentInsight/Detail.aspx?cid=476c4f19-be76-4e89-abbd-aac2b5359729>

Courses, Invited Lectures, and Symposia

1. Invited Speaker. Association for Research in Vision and Ophthalmology, Sarasota, FL, 1990.
2. Course director. "Technical advances in the treatment of refractory glaucoma: drainage implant devices." UT Southwestern Medical Center, Dallas, TX, May 4, 1996.
3. Invited Speaker and Visiting Professor. Candray Eye Clinic, San Salvador, El Salvador, September 18-22, 1997.
4. Invited Speaker. "Ocular Management Pearls for Optometrists," UT Southwestern Medical Center, Dallas TX, September 27, 1998.
5. Invited Speaker. "Ophthalmology Review for the Primary Care Physician," UT Southwestern Medical Center, Dallas, TX, October 17, 1998.
6. Invited Speaker. "Anterior Segment Review for Optometrists," UT Southwestern Medical Center, Dallas, TX, September 26, 1999.
7. Invited Speaker. "Ophthalmology Review for the Primary Care Physician," UT Southwestern Medical Center, Dallas, TX, November 6, 1999.

8. Invited Speaker. American Academy of Ophthalmology annual meeting, Orlando, FL, 1999.
9. Invited Speaker. San Antonio Ophthalmological Association, San Antonio, TX, November 18, 1999.
10. Invited Speaker. Amarillo Ophthalmological Association, Amarillo, TX, February 22, 2000.
11. Invited Speaker. Merck Glaucoma Consultants Meeting, Vail, CO, March 31-April 1, 2000.
12. Invited Speaker. Alcon Laboratories German SOVA Meeting, Ft Worth, TX, April 12, 2000.
13. Invited Speaker. Merck Glaucoma Consultants Meeting, Charleston, SC, April 14-16, 2000.
14. Invited Speaker and Visiting Professor. Resident Alumni Day, Louisiana State University, Shreveport, LA, May 12, 2000.
15. Invited Speaker. Lubbock Eye Club, Lubbock, TX, May 23, 2000.
16. Invited Speaker. 2000 Merck Ophthalmologist Consultants Meeting, Palm Springs, CA, September 8-11, 2000.
17. Invited Speaker. "Posterior Segment Review for Optometrists," UT Southwestern Medical Center, Dallas, TX, September 17, 2000.
18. Invited Speaker. 2000 Merck Ophthalmologist Consultants Meeting, Jackson Hole, WY, September 22-24, 2000.
19. Invited Speaker. "3rd Annual Ophthalmology Review for the Primary Care Physician," UT Southwestern Medical Center, Dallas, TX, October 7, 2000.
20. Invited Speaker. "Ophthalmology Advances in Senior Care – Understanding Ocular Disease, Treatment Options, and Effective Patient Monitoring." Senior Care Pharmacy 2000, Copper Ridge, Colorado, November 4, 2000.
21. Invited Speaker. Alcon Laboratories Japan SOVA Meeting, Dallas, TX, November 13, 2000.

22. Invited Speaker. "Neuroprotection: Connecting Research to Real Practice." Houston, TX, February 22, 2001.
23. Moderator. "Progress in Treatment Modalities for Glaucoma." Satellite Broadcast from The International Glaucoma Society Meeting (Prague), Dallas, TX, March 24, 2001.
24. Invited Speaker. Merck Southwest Regional Glaucoma Meeting, San Antonio, TX, March 30-31, 2001.
25. Invited Speaker and Visiting Professor. University of Utah Department of Ophthalmology Grand Rounds, April 18, 2001.
26. Invited Speaker and Visiting Professor. University of Iowa Department of Ophthalmology Grand Rounds, May 4, 2001.
27. Invited Speaker. "Neuroprotection: Connecting Research to Real Practice" symposium. Chicago, IL, May 17, 2001.
28. Invited Speaker. "Neuroprotection: Connecting Research to Real Practice" symposium. Dallas, TX, June 7, 2001.
29. Invited Speaker. Boise Ophthalmological Association, Boise, ID, June 15, 2001.
30. Invited Speaker. Utah Ophthalmological Society Shakespeare in Summer Meeting, Cedar City, UT, July 20-22, 2001.
31. Invited Speaker. "Anterior Segment Review for Optometrists," UT Southwestern Medical Center, Dallas, TX, October 14, 2001.
32. Invited Speaker. New Orleans Academy of Ophthalmology, October 16, 2001.
33. Invited Speaker. "Glaucoma: A Vascular Perspective" symposium. American Academy of Ophthalmology annual meeting, New Orleans, LA, 2001.
34. Invited Speaker. 2002 Texas Glaucoma Symposium, Dallas, TX, January 18-20, 2002.
35. Invited Speaker. Amarillo Ophthalmological Association, Amarillo, TX, January 30, 2002.

36. Invited Speaker. "Glaucoma Symposium: New Developments and Trends in Pharmaceuticals to Treat Glaucoma." Contact Lens Association of Ophthalmologists annual meeting, Anaheim, CA, January 31-February 3, 2002.
37. Invited Speaker. Evansville Ophthalmological Association, Evansville, IN, February 12, 2002.
38. Invited Speaker. Cedar Sinai Medical Center Ophthalmological Association, Los Angeles, CA, February 27, 2002.
39. Invited Speaker. Lubbock Eye Club, Lubbock, TX, March, 19, 2002
40. Invited Speaker. Alcon Regional Glaucoma Consultants Meeting, Stowe, VT, March 22-24, 2002.
41. Invited Speaker. Alcon Laboratories Japan SOVA Meeting, Dallas, TX, March, 25, 2002.
42. Invited Speaker. Virginia Society of Ophthalmology annual meeting, Williamsburg, VA, April 12, 2002.
43. Moderator. "Hitting the Targets: Update on Glaucoma Therapy," Satellite broadcast from the 29th International Congress of Ophthalmology (Sydney), Dallas, TX, April 22, 2002.
44. Invited Speaker and Visiting Professor. Emory University Department of Ophthalmology, Grand Rounds, April 26, 2002.
45. Invited Speaker. Alcon Regional Glaucoma Consultants Meeting, Orlando, FL, April 26-28, 2002.
46. Invited Speaker. Hartford Ophthalmological Association, Hartford, CT, May 9, 2002.
47. Invited Speaker and Visiting Professor. Il Curso Universitario Internacional de Oftalmologia, Santiago, Chile, July 18-20, 2002.
48. Invited Speaker. Glaucoma Grand Rounds, UT Southwestern Medical Center, Department of Ophthalmology, Dallas, TX, August 30, 2002.

49. Invited Speaker. "3-D Scanning Tomography: Diagnostics for Glaucoma Detection and Management." Dallas, TX, September 28, 2002
50. Course Director. "Clinical Applications of Ocular Bloodflow in Glaucoma and Age-Related Macular Degeneration." UT Southwestern Medical Center, Dallas, TX, October 5, 2002
51. Invited Speaker. "Traumatic Glaucoma: Mechanisms and Management" symposium. American Academy of Ophthalmology annual meeting, Orlando, FL, October 21, 2002.
52. Invited Speaker. "Ocular Hypertension Treatment Study: Translating Evidence into Practice." El Paso, TX, November 12, 2002.
53. Invited Speaker. Northern Virginia Academy of Ophthalmology, Washington, D.C., November 19, 2002.
54. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." St. Louis, MO, December 3, 2002.
55. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." Kansas City, MO, December 17, 2002.
56. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." Atlanta, GA, January 28, 2003.
57. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." Baltimore, MD, January 29, 2003.
58. Invited Speaker. "Glaucoma Management Trends" (Symposium). 4th International Glaucoma Symposium, Barcelona, Spain, March 19-22, 2003.
59. Invited Speaker. "Treating the Patient, Not Just the IOP." 4th International Glaucoma Symposium, Barcelona, Spain, March 19-22, 2003.

60. Invited Speaker. "Making Sense of the Signs of Glaucoma" (Symposium). Dallas, Texas, April 5, 2003.
61. Course Director. "Current Trends in Glaucoma Management." American Society of Cataract and Refractive Surgery, San Francisco, CA, April 12, 2003.
62. Invited Speaker. Glaucoma Academic Advisory Panel, Alcon Laboratories, Colorado Springs, CO. May 16-18, 2003.
63. Course Director. "Diurnal Pressure Control and Combination Therapy," CME teleconference symposium, Spring through Fall, 2003.
64. Course Director. "Adjunctive Glaucoma Therapy: Making Simplified and Rational Choices," CME teleconference symposium, Fall, 2003.
65. Invited Speaker. African American Glaucoma Educational and Speaker Training Meeting, Alcon Laboratories, Chicago, IL, September 5-7, 2003.
66. Invited Speaker. Florida Society of Ophthalmology annual meeting, Sarasota, FL, September 12-14, 2003.
67. Invited Speaker. 6th Annual Anterior Segment Review for Optometrists. UT Southwestern Medical Center, Dallas, TX, October 12, 2003.
68. Invited Speaker. The 57th Congress of Clinical Ophthalmology of Japan, Nagoya, Japan, October 30 – November 2, 2003.
69. Invited Speaker. Trials and Tribulations. Glaucoma Subspecialty Day, American Academy of Ophthalmology annual meeting, November 15, 2003.
70. Course Director. "Breakfast with the Experts" CME Roundtable Program, American Academy of Ophthalmology annual meeting, Anaheim, CA, November 16 and 17, 2003.
71. Course Director. "Adjunctive Glaucoma Therapy: Making Simplified and Rational Choices," CME teleconference symposium, Spring, 2004

72. Course Director. "Glaucoma Management Differences Among Populations: A Focus on Black Patients," CME teleconference symposium, Spring, 2004.
73. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." Charleston, SC, April 6, 2004.
74. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." Los Angeles, CA, April 20, 2004.
75. Invited Speaker. Sociedad Puertorriquena de Oftalmologia, 35th annual meeting, Rio Grande, Puerto Rico, May 28 – 31, 2004.
76. Invited Speaker. American Eye Study Club annual meeting, Banff, Alberta, Canada, August 3 – 7, 2004.
77. Invited Speaker. "FORGE™: Focusing Ophthalmology on Reframing Glaucoma Evaluation" CME Symposium, Grapevine, TX, September 24-26, 2004.
78. Invited Speaker. Greensboro Ophthalmology Journal Club, Greensboro, NC, October 5, 2004.
79. Course Director. "Breakfast with the Experts" CME Roundtable Program, American Academy of Ophthalmology annual meeting, New Orleans, LA, October 25, 2004.
80. Course Director. "Adjunctive Glaucoma Therapy: Making Simplified and Rational Choices," CME teleconference symposium, Fall, 2004.
81. Invited Speaker. "Hear No Evil, See No Evil, Scratch No Evil." Third Annual Clinical Update in Dermatology, Ophthalmology, and Otolaryngology for Primary Care Physicians. UT Southwestern Medical Center, Dallas, TX, February 5, 2005.
82. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." St Louis, MO, March 1, 2005.

83. Course Director. "The Art and Science of Choosing Adjunctive Therapy for Glaucoma Patients," CME teleconference symposium, Spring, 2005.
84. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." Los Angeles, CA, March 23, 2005.
85. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." Atlanta, GA, April 5, 2005.
86. Invited Speaker. "A Comprehensive Approach to Glaucoma Management: Compliance, IOP Control, Adjunctive Therapy and Dual Surgery," EyeWorld educational symposium, American Society of Cataract and Refractive Surgery annual meeting. Washington, DC, April 18, 2005.
87. Invited Speaker. "Glaucoma Management Differences Among Populations: A Focus on Black Patients." Oakland, CA, April 27, 2005.
88. Invited Speaker. "Impact of Central Corneal Measures on Intraocular Pressure," Dallas, TX, May 19, 2005.
89. Invited Speaker. "Challenges in Ophthalmology 2005," American Society of Ophthalmic Registered Nurses annual meeting, Dallas, TX, June 11, 2005.
90. Invited Speaker. "Glaucoma: Improving Your Odds," Third Annual Ocular Surgery News Symposium, Las Vegas, NV, June 17-18, 2005.
91. Invited Speaker. African American Glaucoma Advisory Summit, Alcon Laboratories, Inc., Ft Worth, TX, July 15 – 16, 2005.
92. Invited Speaker. American Eye Study Club annual meeting, Santa Ana Pueblo, NM, August 2 – 6, 2005.
93. Invited Speaker. "SURGE™: Sound Understanding of Real Glaucoma Efficacy" CME Symposium, Dallas, TX, September 15, 2005.

94. Course Director. "Breakfast with the Experts" CME Roundtable Program, American Academy of Ophthalmology annual meeting, Chicago, IL, October 16, 2005.
95. Invited Speaker. Joint Commission on Allied Health Personnel in Ophthalmology's 33rd Annual Continuing Education Program, Chicago, IL, October 16, 2005.
96. Invited Speaker. "Management of Eyes with Trauma-Related Hypotony" symposium. American Academy of Ophthalmology annual meeting, Chicago, IL, October 18, 2005.
97. Invited Speaker. Volusia County Ophthalmological Society, Ormond Beach, FL, October 27, 2005.
98. Invited Speaker. "Treatment of Risk in the Glaucoma Continuum Regional Symposium," San Francisco, CA, November 5, 2005.
99. Invited Speaker. Peninsula Eye Society, San Jose, CA, February 1, 2006.
100. Invited Speaker. "Treatment of Risk in the Glaucoma Continuum Regional Symposium," Dallas, TX, February 4, 2006.
101. Invited Speaker. "Strategies to Prevent Disease Progression," Glaucoma Regional Consultant Meeting, Allergan, Inc., Las Vegas, NV, February 24 – 26, 2006.
102. Invited Speaker. "GREAT Expectations: Glaucoma Risk Evaluation and Treatment," CME meeting, Houston, TX, March 7, 2006.
103. Course Director. "Adjunctive Medical Therapy: What to do after the PGA," CME teleconference symposium, Spring, 2006.
104. Invited Speaker. American Eye Study Club annual meeting, New Castle, NH, July 25 – 28, 2006.
105. Invited Speaker. Glaucoma Educators Meeting, Alcon Laboratories, San Diego, CA, July 28 – 30, 2006.
106. Invited Speaker. 2006 Australian Glaucoma Management Trends Meeting, Alcon Laboratories, Cairns, Australia, August 8 – 10, 2006.

107. Invited Speaker. Glaucoma Fellows Program CME Symposium, Alcon Laboratories, Inc., Ft Worth, TX, October 6 - 8, 2006.
108. Invited Speaker. "Helping Improve Therapeutic Success," Glaucoma Advisory Summit, Alcon Laboratories, Tucson, AZ, October 27 - 29, 2006.
109. Invited Speaker. Glaucoma Advisory Panel, Alcon Laboratories, Las Vegas, NV, November 8 - 10, 2006.
110. Invited Speaker. "Fixed Combination Treatment for Glaucoma Management," CME meeting, Beverly Hills, CA, November 30, 2006.
111. Invited Speaker. "Ophthalmology at the Crossroads: Still Crossing the Road 2006," CME symposium, UT Southwestern Medical Center, Dallas, TX, December 9, 2006.
112. Invited Speaker. "Fixed Combination Treatment for Glaucoma Management," CME meeting, Seattle WA, January 23, 2007.
113. Invited Speaker. "Hear No Evil, See No Evil, Scratch No Evil." Fifth Annual Clinical Update in Dermatology, Ophthalmology, and Otolaryngology for Primary Care Physicians. UT Southwestern Medical Center, Dallas, TX, February 10, 2007.
114. Invited Speaker. "Helping Improve Therapeutic Success," Glaucoma Advisory Summit, Alcon Laboratories, Tucson, AZ, March 9 - 11, 2007.
115. Invited Speaker. "Monotherapy Options: Glaucoma Management Consultant Meeting," Allergan, Inc., Washington D.C., April 20 - 22, 2007.
116. Course Director. "John R. Lynn, M.D. Lectureship in Ophthalmology," CME symposium, UT Southwestern Medical Center, Dallas, TX, May 19, 2007.
117. Invited Speaker. Florida Society of Ophthalmology annual meeting, Orlando, FL, June 24, 2007.
118. Course Director. "Minimizing the Impact of Glaucoma Therapy on the Ocular Surface," CME teleconference symposium, Summer and Fall, 2007.

119. Invited Speaker. Ophthalmic Update 2007, American Society of Ophthalmic Registered Nurses, Ft Worth, TX, July 21, 2007.
120. Invited Speaker. "Helping Improve Therapeutic Success," Glaucoma Advisory Summit, Alcon Laboratories, Toronto, Canada, September 7 – 9, 2007.
121. Moderator. "Ophthalmology at the Crossroads: Not Across Yet 2007," CME symposium, UT Southwestern Medical Center, Dallas, TX, December 1, 2007.
122. Visiting Professor. Scott and White Eye Institute, Journal Club, January 30, 2008, Temple, TX.
123. Invited Speaker. Des Moines Ophthalmological Society, February 7, 2008, Des Moines, IA.
124. Invited Speaker. Tarrant County Ophthalmological Society, May 1, 2008, Fort Worth, TX.
125. Course Director. "John R. Lynn, M.D. Lectureship in Ophthalmology," CME symposium, UT Southwestern Medical Center, Dallas, TX, May 10, 2008.
126. Invited Speaker. "Helping Improve Therapeutic Success," Glaucoma Advisory Summit, Alcon Laboratories, Hollywood, FL, May 16 – 18, 2008.
127. Invited Speaker. "CORE: Complementary Ophthalmic Residents Education," CME symposium, Alcon Laboratories, Dallas, TX, September 13, 2008.
128. Invited Speaker. "Helping Improve Therapeutic Success," Glaucoma Advisory Summit, Alcon Laboratories, Chicago, IL, September 19 – 21, 2008.
129. Moderator. Glaucoma Paper Session, American Academy of Ophthalmology annual meeting, Atlanta, GA, November 10, 2008.
130. Invited Speaker. Alcon Protocol C-08-050 Investigator/Study Coordinator Meeting, Alcon Laboratories, Dallas, TX, November 21 – 22, 2008.

131. Invited Speaker. Adjunctive Medical Therapy: New Evidence and Treatment Strategies. CME meeting, Buffalo, NY, April 1, 2009.
132. Invited Speaker. Adjunctive Medical Therapy: New Evidence and Treatment Strategies. CME meeting, Brooklyn, NY, April 22, 2009.
133. Invited Speaker. Adjunctive Medical Therapy: New Evidence and Treatment Strategies. CME meeting, Miami, FL, May 6, 2009.
134. Invited Speaker. Adjunctive Medical Therapy: New Evidence and Treatment Strategies. CME meeting, Raleigh, NC, May 20, 2009.
135. Course Director. "John R. Lynn, M.D. Lectureship in Ophthalmology," CME symposium, UT Southwestern Medical Center, Dallas, TX, May 30, 2009.
136. Invited Speaker. Adjunctive Medical Therapy: New Evidence and Treatment Strategies. CME meeting, Houston, TX, June 23, 2009.
137. Course Director. CPE Glaucoma Fellows Program and Wet Lab. Alcon Laboratories, Fort Worth, TX, November 12 – 15, 2009.
138. Invited Speaker. The Need for an Alternative Preservative in IOP-Lowering Medications. CME meeting, Minneapolis, MN, January 20, 2010.
139. Invited Speaker. The Need for an Alternative Preservative in IOP-Lowering Medications. CME meeting, Atlanta, GA, March 24, 2010.
140. Invited Speaker. The Need for an Alternative Preservative in IOP-Lowering Medications. CME meeting, Denver, CO, April 21, 2010.
141. Course Director. "John R. Lynn, M.D. Lectureship in Ophthalmology," CME symposium, UT Southwestern Medical Center, Dallas, TX, May 15, 2010.
142. Invited Speaker. New Perspectives on Glaucoma and Ocular Surface Disease. CME meeting, Los Angeles, CA, June 2, 2010.
143. Invited Speaker. 13th Annual Ophthalmology Review for the Primary Care Physician. CME symposium, UT Southwestern Medical Center, Dallas, TX, November 7, 2010.

144. Invited Speaker. Pediatric Glaucoma for "Dummies" (AKA Adult Glaucomatologists) Symposium, American Glaucoma Society annual meeting, Dana Point, CA, March 5, 2011.
145. Invited Speaker. Ophthalmic Management Trends Symposium – Middle East SOVA. Alcon Laboratories, Fort Worth, TX, May 4, 2011.
146. Course Director. "John R. Lynn, M.D. Lectureship in Ophthalmology," CME symposium, UT Southwestern Medical Center, Dallas, TX, May 7, 2011.
147. Invited Speaker. Glaucoma Speakers Training Meeting, Alcon Laboratories, Inc., Chicago, IL, August 19 – 20, 2011.

Grant History

1. New World Medical, Inc. 1996
Technical Advances in the Treatment of Refractory Glaucoma:
Drainage Implant Devices.
Course Director
\$15,000
2. Alcon Research, Ltd. 1998
A Six-Month, Triple-Masked, Parallel Group, Primary Therapy Study of
the Safety and Efficacy of AL-6221 0.0015% and AL-6221 0.004%
Compared to Timoptic 0.5% in Patients with Open Angle Glaucoma
or Ocular Hypertension.
Primary Investigator
\$41,200
3. Alcon Research, Ltd. 1999
An Open-Label Study of the Ocular Tissue Distribution of Betaxolol
Ophthalmic Suspension in Patients Requiring Enucleation for
Glaucoma- Related Ocular Pain/Blindness.
Primary Investigator
\$6500

4. Merck and Co., Inc. 2001
Comparison of the Intraocular Pressure Effect and Safety of Dorzolamide 2% vs. Brimonidine 0.2%, Each Given Three Times Daily for Six Weeks in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
Primary Investigator
\$22,812
5. Alcon Research, Ltd. 2001
A Twelve-Week, Multicenter, Double-Masked, Parallel Group, Primary Therapy Study of the Safety and Efficacy of Betoptic 0.25% Compared to Timolol Gel Forming Solution 0.25% and 0.5% in Pediatric Patients with Glaucoma or Ocular Hypertension.
Primary Investigator
\$13,600
6. Alcon Research, Ltd. 2001
A Twelve-Week, Multicenter, Double-Masked, Parallel Group, Primary Therapy Study of the Safety and Efficacy of Betaxon 0.5% Compared to Azopt 1% in Pediatric Patients with Glaucoma or Ocular Hypertension
Primary Investigator
\$14,500
7. Merck and Co., Inc. 2002
Clinical Applications of Ocular Bloodflow in Glaucoma and Age-Related Macular Degeneration.
Course Director
\$50,850
8. Alcon Research, Ltd. 2002
An Open-Label, Multiple-Dose, Pharmacokinetic Study of Aqueous Humor Concentrations of AL-5848 Following Topical Ocular Administration of Travatan® (Travoprost Ophthalmic Solution) 0.004% for at least 21 Days in Patients with Open-Angle Glaucoma and/or Ocular Hypertension Undergoing Cataract Surgery.
Ocular Hypertension Undergoing Cataract Surgery.
Primary Investigator
\$23,393

9. Alcon Research, Ltd. 2003
A Three-Month, Randomized, Double-Masked, Parallel Group, Primary Therapy Study with a Planned Nine-Month Extension, of the Safety and IOP-Lowering Efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% Compared to Alphagan® P, 0.15% in Patients with Open-Angle Glaucoma or Ocular Hypertension.
Primary Investigator
\$101,000
10. Alcon Research, Ltd. 2003
An Open-Label, Multiple-Dose, Pharmacokinetic Study of Bimatoprost Ophthalmic Solution 0.03% in Aqueous Humor Following Topical Ocular Administration in Patients with Open-Angle Glaucoma and Ocular Hypertension.
Primary Investigator
\$26,038
11. Alcon Research, Ltd. 2004
A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment with TRAVATAN 0.004% Ophthalmic Solution.
Primary Investigator
\$13,900
12. Alcon Research, Ltd. 2004
A Five-Year Multicenter, Commercial Label Safety Study of TRAVATAN 0.004% in Subjects with TRAVATAN induced Iris Pigmentation Changes
Primary Investigator
\$12,280
13. Alcon Research, Ltd. 2006
Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs. COSOPT® in Patients with Open-Angle Glaucoma or Ocular Hypertension
Primary Investigator
\$71,725

14. Merck and Co., Inc./University of Tennessee Health Science Center
2006
Comparison of Twice Daily and Three Times Daily Dosing of
Dorzolamide in Ocular Hypertensive and Glaucoma Patients
Treated with Prostaglandin Analogs
Co-Investigator
\$29,320

15. Allergan Sales, LLC. 2007
A multicenter, masked evaluation of ocular surface tolerability
associated with bimatoprost 0.03%, travoprost 0.004% (BAK free)
or latanoprost 0.005% therapy in patients with glaucoma or ocular
hypertension.
Primary Investigator
\$36,400

16. Alcon Research, Ltd. 2011
A Three-Month, Randomized, Double-Masked, Parallel-Group Study
with a Planned Three-Month Safety Extension of the Efficacy and
Safety of a Fixed Combination of Brinzolamide 1%/Brimonidine 0.2%
compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three
Times Daily in Patients with Open-Angle Glaucoma and/or Ocular
Hypertension
Primary Investigator
\$47,000

Postdoctoral Trainees

Glaucoma
Fellows

Jeffrey Piper, M.D.	Middlebury, VT
Trang Le, M.D.	Duncanville, TX
Joseph Pham, M.D.	Spokane, WA
Ozlem Abbasoglu, M.D.	Ankara, Turkey
Nimisha Patel, M.D.	Houston, TX
Andrea Harper, M.D.	New York, NY
Kimberly Warren, M.D.	Dallas, TX
Anne Miller, M.D.	Cheyenne, WY
John Hazelton, M.D.	Myrtle Beach, SC
Dharmendra Patel, M.D.	Scottsdale, AZ
Chanping Liang, M.D.	Shreveport, LA
Robert Marquis, M.D., Ph.D.	Austin, TX
Adam Dossey, M.D.	Tyler, TX
Colleen Coleman, M.D.	Philadelphia, PA
Nalini Aggarwal, M.D.	Dallas, TX
Mark Gallardo, M.D.	El Paso, TX
Jason Tokunaga, M.D.	Honolulu, HI
Lani Vu, M.D.	Naples, FL
Kyle Rhodes, M.D.	Austin, TX
Danny Kim, M.D.	Los Angeles, CA
Robert Saltzmann, M.D.	Charlotte, NC
John Nicolau, M.D.	San Antonio, TX
Shamil Patel, M.D.	Phoenix, AZ
Carl Sloan, M.D.	Myrtle Beach, SC
Felise May Barte, M.D.	
Yen Ngo, M.D.	